Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Smallpox Vaccine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects

NCT00565929
View directory record Official record
Conditions
Variola Major (Smallpox)
Interventions
Placebo, MVA-BN
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional

Evaluation and Treatment of Eye Complications of Vaccinia Vaccination

NCT00081835
View directory record Official record
Conditions
Vaccinia
Interventions
NP-016 Vaccine Immune Globulin (IV-VIG)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Year and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 11:38 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

NCT00053508
View directory record Official record
Conditions
Smallpox
Interventions
ACAM1000, vaccinia virus (calf lymph) smallpox vaccine: Dryvax
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 29 Years
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
3
States / cities
Orlando, Florida • Rochester, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Immune Responses Smallpox

NCT00068198
View directory record Official record
Conditions
Smallpox
Interventions
Dryvax
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 9, 2026, 11:38 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

NCT00389103
View directory record Official record
Conditions
Smallpox, Atopic Dermatitis
Interventions
MVA (smallpox vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ACAM 3000 MVA at Harvard Medical School

NCT00133575
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

NCT00002261
View directory record Official record
Conditions
HIV Infections
Interventions
Smallpox Vaccine, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2007 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT

NCT00038987
View directory record Official record
Conditions
Smallpox
Interventions
Wetvax (APSV)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
4
States / cities
Oakland, California • Iowa City, Iowa • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001043
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 Vaccine (Immuno-AG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 9, 2026, 11:38 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

NCT00282581
View directory record Official record
Conditions
HIV Infections, Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

NCT01827371
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
435 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
6
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox

NCT00053742
View directory record Official record
Conditions
Healthy
Interventions
Modified Vaccinia Virus Ankara TBC-MVA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

NCT00079820
View directory record Official record
Conditions
Smallpox
Interventions
ACAM3000 MVA Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 31 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 9, 2026, 11:38 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers

NCT00103584
View directory record Official record
Conditions
Smallpox
Interventions
LC16m8 Smallpox Vaccine
Biological
Lead sponsor
VaxGen
Industry
Eligibility
18 Years to 34 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
4
States / cities
Stanford, California • Lexington, Kentucky • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2007 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®

NCT00042094
View directory record Official record
Conditions
Smallpox
Interventions
Cell-Cultured Smallpox Vaccine compared to Dryvax®
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

NCT01668537
View directory record Official record
Conditions
Smallpox
Interventions
LF formulation of IMVAMUNE®, FD formulation of IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
South Miami, Florida • Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

NCT01158157
View directory record Official record
Conditions
Smallpox Vaccine Adverse Reaction
Interventions
ACAM2000
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Altamonte Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 9, 2026, 11:38 PM EDT
Completed No phase listed Observational

Immune Responses to Smallpox Vaccination

NCT00325975
View directory record Official record
Conditions
Smallpox Vaccine
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 9, 2026, 11:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

NCT00928577
View directory record Official record
Conditions
Smallpox
Interventions
Not listed
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
17 Years and older
Enrollment
14,108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
4
States / cities
Twentynine Palms, California • Fort Campbell North, Kentucky • Fort Bliss, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

NCT00316602
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

NCT00189904
View directory record Official record
Conditions
HIV Infections
Interventions
IMVAMUNE (MVA-BN)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
151 participants
Timeline
Started 2005
U.S. locations
5
States / cities
Indianapolis, Indiana • Lexington, Kentucky • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

NCT00053495
View directory record Official record
Conditions
Smallpox
Interventions
Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 29 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
4
States / cities
Orlando, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

NCT00316589
View directory record Official record
Conditions
HIV Infections
Interventions
IMVAMUNE (MVA-BN)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Burbank, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 9, 2026, 11:38 PM EDT